Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure
Robert D Winslow, Sean Pinney and Valentin Fuster*
Correspondence *Box 1030, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
Email valentin.fuster@mountsinai.org
The need for improved prevention of sudden cardiac death has led physicians to increase the use of implantable cardioverter-defibrillators. Despite data now being available from a variety of studies, how to identify patients who will benefit most from this invasive and expensive therapy is still unclear. Here, the impact of findings on clinical decision-making is explored.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatmentKidney International Original Article
See all 12 matches for Research